Creative Medical Technology Holdings Inc CELZ

$0.67 0.00 (-0.69%)

Valuation

Market cap
4,747,000
Revenue TTM
$10,000
Net income TTM
$-6,000,000
PE ratio
0.00
Forward PE
—
Profit margin
-60,000.00%
Debt to equity
0.00

Trading

Volume
49,030
Avg volume
799,890
Day's range
$0.67 – $0.72
Shares out
6,593,000
Stochastic %K
6%
Beta
2.06
Analysts
Sell
Price target
$20.00

Price

Company profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human...

Show more

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Industry
Biotechnology
Sector
Healthcare
Phone
480 399 2822
Website
https://www.creativemedicaltechnology.com
Address
211 East Osborn Road, Phoenix, United States

Latest news

Stocktwits

FroNOBaggins Oct 29, 5:41 PM
$CELZ What kind of publicly traded company allows its official Investor Relations email channel to remain broken for months, repeatedly bouncing shareholder inquiries? I just tested [email protected] again today, October 29. Same result. Mailbox is full & message undeliverable. Meanwhile, CELZ's official IR representative continues publishing promotional posts about the company's technology! How can shareholders have confidence in management's commitment to transparency and accountability when the company cannot even maintain a functioning email inbox for its investors? If management has time to allocate shareholder capital into speculative investments through Bionance, an entity in which Warbington personally holds an ownership interest, surely it can find time to ensure the company's IR mailbox works and shareholders receive responses to legitimate questions.
0 replies
SWEEN24 Oct 29, 3:23 PM
$CELZ are we gonna move or just sit here.
0 replies
CreativeMedical_IR Oct 29, 1:51 PM
Olastrocel is the clinical program investors see. AlloStem™ is part of the platform behind it. $CELZ has developed AlloStem™ as an off-the-shelf, donor-derived cell platform supported by a Master Cell Bank and Drug Master File—infrastructure designed to support product consistency, scale-up, and future regulatory submissions. Olastrocel (CELZ-201), the Company’s lead clinical candidate, was developed on this platform. Platform → Clinical Programs → Multiple Development Paths For CELZ, the opportunity extends beyond advancing a single asset: it includes building technology that can support development across multiple indications.
1 replies
SWEEN24 Oct 28, 6:44 PM
$CELZ closed the daily gap in a demand zone. Lets see what happens.
0 replies
FroNOBaggins Oct 28, 2:03 PM
$CELZ On January 6, 2026, $CELZ issued a press release declaring BioDefense a "wholly owned subsidiary of Creative Medical." On September 25, CELZ filed an 8-K revealing that the company had purchased an additional 20% of BioDefense from Creative Acquisition Corp. (CAC), a company indirectly wholly owned by CEO Timothy Warbington, for $200,000 CASH + 1 MILLION CELZ SHARES! But here's the astonishing part. The agreement establishes that Warbington's company already owned 40% of BioDefense** before the transaction. It still owns 20% afterward! I've reviewed the intervening SEC filings and cannot find an explanation for the discrepancy. How did BioDefense go from being described as 100% owned by CELZ in January to only 60% owned in September? When and how did Warbington's company acquire its 40% interest? The transaction increased CELZ's outstanding shares from approximately **6.59 MILLION to 7.59 MILLION, a 15.2% increase! CONTINUED 👇🏻
0 replies
FroNOBaggins Oct 28, 2:02 PM
$CELZ Warbington received approximately $1.84 MILLION in reported compensation during 2023–2025**, excluding 2026 compensation. His privately owned company has now received another $200K in cash and 1 MILLION CELZ shares! Meanwhile, CELZ has spent approximately $7.6 MILLION on companywide R&D since 2023, substantially diluted shareholders, and accumulated a $73.5 MILLION deficit. Directors Dickerson, Snow, Finger and Urdang: How did CAC obtain 40% of BioDefense? Who approved the September transaction? Was an independent valuation conducted, and did interested directors recuse themselves? Why is a company preparing for a potentially expensive Phase 3 trial paying its CEO's privately owned company $200K plus 1 MILLION shares for an additional interest in a subsidiary whose initiatives CELZ has publicly described as relying on its own proprietary technology? Shareholders deserve a complete explanation of the ownership history, valuation, and board approval process.
0 replies
ReturnOfEsquire Oct 28, 1:46 PM
$CELZ Down 42% since first post.
1 replies
CreativeMedical_IR Oct 28, 12:51 PM
One clinical program may lead the story. But it doesn’t define the entire company. Olastrocel is $CELZ’s most advanced clinical program, while the Company’s broader platform extends across regenerative medicine and immunotherapy, supported by programs and intellectual property at different stages of development. That creates more than one potential path forward-from clinical development to technology advancement and potential strategic opportunities. Lead Program → Broader Pipeline → Intellectual Property As Olastrocel advances, the broader CELZ platform provides additional programs and technologies to follow.
0 replies